Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Wally R. Smith, Alexander Glaros et al.|The Lancet Haematology|2024Cited by 25
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Mitapivat in Patients with Sickle Cell DiseaseJoanna Howard, Swee Lay Thien, Kevin H.M. Kuo et al.|Blood|2021Cited by 4
Burden of Illness of Alpha- and Beta-Thalassemia: A Qualitative StudySujit Sheth, Kevin H.M. Kuo, Alexander Glaros et al.|Blood|2023Cited by 2
Clinically meaningful improvements in patient‐reported outcomes in mitapivat‐treated patients with pyruvate kinase deficiencyKevin H.M. Kuo, Hanny Al‐Samkari, Rachael F. Grace et al.|American Journal of Hematology|2024Cited by 2